Alliance Global Partners assumed coverage on shares of Chromocell Therapeutics (NYSE:CHRO – Free Report) in a report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating on the stock.
Chromocell Therapeutics Stock Performance
Shares of NYSE CHRO opened at $1.37 on Tuesday. Chromocell Therapeutics has a 1-year low of $1.21 and a 1-year high of $6.00. The firm’s 50-day moving average price is $1.60.
Chromocell Therapeutics (NYSE:CHRO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.55) earnings per share for the quarter.
Hedge Funds Weigh In On Chromocell Therapeutics
About Chromocell Therapeutics
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
See Also
- Five stocks we like better than Chromocell Therapeutics
- What is the S&P/TSX Index?
- Sarepta Therapeutics Stock Soars on FDA Approval
- Business Services Stocks Investing
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Chromocell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromocell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.